Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 24 11:37AM ET
12.26
Dollar change
+0.21
Percentage change
1.71
%
Index- P/E- EPS (ttm)-1.95 Insider Own10.09% Shs Outstand107.08M Perf Week1.76%
Market Cap1.31B Forward P/E- EPS next Y-1.83 Insider Trans-0.10% Shs Float96.28M Perf Month-7.11%
Income-207.04M PEG- EPS next Q-0.42 Inst Own84.71% Short Float5.20% Perf Quarter-12.45%
Sales509.34M P/S2.58 EPS this Y9.89% Inst Trans2.97% Short Ratio3.93 Perf Half Y-12.85%
Book/sh3.39 P/B3.62 EPS next Y-4.31% ROA-17.71% Short Interest5.01M Perf Year-80.58%
Cash/sh8.52 P/C1.44 EPS next 5Y- ROE-51.52% 52W Range10.87 - 83.60 Perf YTD-17.87%
Dividend Est.- P/FCF- EPS past 5Y-22.97% ROI-21.60% 52W High-85.33% Beta0.49
Dividend TTM- Quick Ratio5.56 Sales past 5Y17.16% Gross Margin74.91% 52W Low12.80% ATR (14)0.76
Dividend Ex-Date- Current Ratio5.78 EPS Y/Y TTM-120.47% Oper. Margin-45.63% RSI (14)38.12 Volatility4.47% 6.34%
Employees1453 Debt/Eq1.67 Sales Y/Y TTM-5.30% Profit Margin-40.65% Recom2.14 Target Price25.86
Option/ShortYes / Yes LT Debt/Eq1.64 EPS Q/Q-23.90% Payout- Rel Volume0.53 Prev Close12.06
Sales Surprise-0.01% EPS Surprise13.69% Sales Q/Q4.17% EarningsMay 02 BMO Avg Volume1.27M Price12.26
SMA20-9.94% SMA50-16.12% SMA200-32.26% Trades Volume241,768 Change1.71%
Date Action Analyst Rating Change Price Target Change
Nov-20-23Resumed JP Morgan Neutral $15
Aug-28-23Downgrade H.C. Wainwright Buy → Neutral $85 → $25
Aug-08-23Upgrade Piper Sandler Neutral → Overweight $45
Aug-04-23Initiated SVB Securities Outperform $51
Jul-31-23Upgrade Evercore ISI Underperform → In-line $33
Jun-07-23Upgrade Wedbush Underperform → Neutral $53 → $46
May-16-23Upgrade Wells Fargo Equal Weight → Overweight $70 → $104
Mar-17-23Downgrade JP Morgan Neutral → Underweight $99 → $50
Jan-06-23Downgrade Wells Fargo Overweight → Equal Weight $89 → $107
Jan-05-23Reiterated H.C. Wainwright Buy $100 → $140
Today 10:45AM
Apr-05-24 07:00AM
Apr-04-24 11:33AM
Apr-01-24 12:00PM
07:00AM
06:34AM Loading…
Mar-30-24 06:34AM
Mar-28-24 11:50AM
05:01AM
Mar-27-24 04:08PM
09:29AM
09:16AM
07:14AM
07:12AM
07:05AM
07:00AM
09:55AM Loading…
Mar-13-24 09:55AM
Mar-11-24 07:00AM
Feb-23-24 11:43AM
Feb-22-24 12:15PM
08:25AM
07:36AM
07:23AM
07:00AM
Jan-19-24 07:46AM
Jan-18-24 02:19PM
07:00AM
Jan-11-24 09:55AM
Jan-09-24 07:00AM
Jan-08-24 07:00AM
Jan-04-24 04:05PM
07:00AM Loading…
Dec-27-23 07:00AM
Dec-08-23 04:09AM
Dec-04-23 04:46PM
Nov-28-23 10:51AM
07:30AM
Nov-21-23 07:00AM
Nov-14-23 09:09AM
Nov-10-23 08:00AM
Nov-03-23 06:45AM
Oct-30-23 02:04AM
Oct-28-23 08:39AM
Oct-26-23 04:35PM
11:00AM
08:52AM
08:30AM
07:24AM
07:00AM
Oct-15-23 06:05PM
Oct-12-23 08:00AM
Oct-02-23 07:00AM
Sep-29-23 05:00PM
Sep-18-23 11:47AM
Sep-08-23 04:01PM
Sep-06-23 02:27PM
Sep-04-23 09:30AM
Aug-31-23 06:52PM
09:55AM
Aug-29-23 06:31PM
Aug-28-23 05:15PM
04:08PM
02:19PM
12:21PM
12:16PM
12:10PM
11:47AM
09:34AM
07:27AM
07:10AM
07:00AM
Aug-25-23 08:20AM
07:00AM
Aug-15-23 09:30AM
Aug-13-23 05:49PM
Aug-09-23 10:45AM
05:10AM
Aug-08-23 04:11PM
10:02AM
Aug-04-23 09:38AM
Aug-01-23 03:54PM
Jul-27-23 06:56PM
11:30AM
08:15AM
07:07AM
07:00AM
Jul-25-23 10:01AM
Jul-21-23 08:00AM
Jul-06-23 01:17PM
Jul-03-23 08:00AM
Jun-12-23 09:30AM
05:39AM
Jun-09-23 09:45AM
Jun-07-23 11:05AM
Jun-06-23 04:02PM
04:01PM
03:40PM
02:48PM
11:50AM
10:31AM
08:31AM
08:12AM
NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GROENHUYSEN WILHELMUS CMChief Operating OfficerMar 04 '24Sale16.011,21719,484251,235Mar 05 04:09 PM
Leonard Frank XEVP, Pres., Novocure OncologyMar 04 '24Sale16.0184013,448160,098Mar 05 04:08 PM
GROENHUYSEN WILHELMUS CMChief Operating OfficerMar 01 '24Sale16.032,10733,769252,452Mar 05 04:09 PM
Leonard Frank XEVP, Pres., Novocure OncologyMar 01 '24Sale16.031,67926,909160,938Mar 05 04:08 PM
GROENHUYSEN WILHELMUS CMChief Operating OfficerFeb 28 '24Sale16.142,30337,177254,559Feb 29 04:28 PM
Leonard Frank XEVP, Pres., Novocure OncologyFeb 28 '24Sale16.142,07833,545162,617Feb 29 04:38 PM
Shah PriteshChief Growth OfficerNov 07 '23Sale12.653824,832124,511Nov 08 04:22 PM
Cordova AshleyChief Financial OfficerNov 02 '23Option Exercise11.461752,006117,618Nov 02 04:20 PM
Cordova AshleyChief Financial OfficerOct 31 '23Option Exercise9.5817,793170,447117,443Nov 02 04:20 PM
Cordova AshleyChief Financial OfficerSep 01 '23Sale21.8288319,26599,650Sep 05 04:24 PM
GROENHUYSEN WILHELMUS CMChief Operating OfficerSep 01 '23Sale21.822946,414209,825Sep 05 04:24 PM
Shah PriteshChief Growth OfficerSep 01 '23Sale21.822735,956124,893Sep 05 04:23 PM
Cordova AshleyChief Financial OfficerAug 02 '23Sale30.251,14434,607100,533Aug 04 04:02 PM